X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
TORRENT PHARMACEUTICALS LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

TORRENT PHARMACEUTICALS LIMITED  (TORR)


Here is the latest financial fact sheet of Torrent Pharma. For more details, see the Torrent Pharma quarterly results and Torrent Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
torrent pharma - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 1,418.3       No. of shares m 169.26
    Mkt Cap Rs m 240,053       % ch % 0.4
    Vol '000 3.5       % ch week % -2.5
    P/E X 22.1       % ch 1-mth % 1.0
    P/CF X 12.2       % ch 12-mth % -1.8
    EPS (TTM) Rs 64.1       52 week H/L Rs 1,767.8/1,185.6
(As on Apr 28, 2017 01:40:00 PM) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs6877675781,2321,720 
Low Rs4995973345231,134 
Sales per share (Unadj.) Rs318.6379.5247.3275.0394.5 
Earnings per share (Unadj.) Rs33.651.139.244.4101.8 
Diluted earnings per shareRs16.825.639.244.4101.8 
Cash flow per share (Unadj.) Rs43.260.944.455.6116.3 
Dividends per share (Unadj.) Rs8.5023.0010.0011.2540.00 
Adj. dividends per shareRs4.2511.5010.0011.2539.99 
Dividend yield (eoy) %1.43.42.21.32.8 
Book value per share (Unadj.) Rs141.1168.1112.4147.2200.3 
Adj. book value per shareRs70.584.0112.4147.1200.2 
Shares outstanding (eoy) m84.6184.61169.22169.22169.22 
Bonus/Rights/Conversions  --B1:1-- 
Price / Sales ratio x1.91.81.83.23.6 
Avg P/E ratio x17.713.311.619.814.0 
P/CF ratio (eoy) x13.711.210.315.812.3 
Price / Book Value ratio x4.24.14.16.07.1 
Dividend payout %25.345.025.525.439.3 
Avg Mkt Cap Rs m50,17457,70477,190148,465241,435 
No. of employees `0009.29.69.511.010.9 
Total wages/salary Rs m5,3186,2337,4118,4188,559 
Avg. sales/employee Rs Th2,946.43,354.04,386.54,212.46,129.6 
Avg. wages/employee Rs Th581.2651.0776.8762.0785.8 
Avg. net profit/employee Rs Th310.4452.0695.9679.81,581.3 
  INCOME DATA
Net Sales Rs m26,95932,11141,84746,53566,764 
Other income Rs m4454343812,8562,156 
Total revenues Rs m27,40432,54542,22949,39068,920 
Gross profit Rs m5,0066,9229,51510,20227,204 
Depreciation Rs m8178278701,9072,461 
Interest Rs m3953385861,7521,859 
Profit before tax Rs m4,2406,1918,4409,39825,041 
Minority Interest Rs m-23-22000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-654-37500-1,403 
Tax Rs m7231,4671,8011,8886,414 
Profit after tax Rs m2,8404,3286,6397,50917,224 
Gross profit margin %18.621.622.721.940.7 
Effective tax rate %17.123.721.320.125.6 
Net profit margin %10.513.515.916.125.8 
  BALANCE SHEET DATA
Current assets Rs m19,87125,60934,04540,51446,622 
Current liabilities Rs m13,62817,10721,74628,23832,843 
Net working cap to sales %23.226.529.426.420.6 
Current ratio x1.51.51.61.41.4 
Inventory Days Days72105888474 
Debtors Days Days71789612579 
Net fixed assets Rs m9,15711,05114,09534,95139,029 
Share capital Rs m423423846846846 
"Free" reserves Rs m11,45313,63417,27222,94331,400 
Net worth Rs m11,93814,21919,02424,90633,890 
Long term debt Rs m3,2214,5457,44521,85218,637 
Total assets Rs m30,59737,83950,69879,03890,136 
Interest coverage x11.719.315.46.414.5 
Debt to equity ratio x0.30.30.40.90.5 
Sales to assets ratio x0.90.80.80.60.7 
Return on assets %10.612.314.311.721.2 
Return on equity %23.830.434.930.250.8 
Return on capital %26.132.734.123.848.5 
Exports to sales %28.137.737.430.443.3 
Imports to sales %8.27.68.26.06.9 
Exports (fob) Rs m7,58512,11415,66514,13628,934 
Imports (cif) Rs m2,2082,4333,4162,8014,584 
Fx inflow Rs m8,15013,22816,86214,26529,185 
Fx outflow Rs m3,5484,7345,1965,1846,021 
Net fx Rs m4,6038,49411,6669,08123,165 
  CASH FLOW
From Operations Rs m 4,991 1,535 5,994 8,102 27,132 
From Investments Rs m -1,370 -2,417 -3,558 -21,623 -7,014 
From Financial Activity Rs m -1,927 197 864 12,123 -14,352 
Net Cashflow Rs m 1,694 -685 3,300 -1,399 5,767 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for torrent pharmaceuticals limited

 Share Holding
Indian Promoters : 71.5%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 7.0%
FIIs : 12.6%
ADR/GDR : 0.0%
Free float : 8.8%
Shareholders : 26,511
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: Torrent House, Off Ashram Road, Ahmedabad - 380 009
    E-MAIL: maheshagrawal@torrentpharma.com     WEB: www.torrentpharma.com
    TELEPHONE: (079) 2658 5090     FAX: (079) 2658 2100
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
    AUDITOR: Deloitte Haskins & Sells
CHM: Sudhir Mehta COMP SEC: Mahesh Agarwal YEAR OF INC: 1973 BSE CODE: 500420 FV (Rs): 5 DIV YIELD (%): 2.8

More pharmaceuticals Company Fact Sheets:   LUPIN LTDINDOCO REMEDIESDISHMAN PHARMAPANACEA BIOTECHGSK PHARMA


Today's Market

Sensex Trades in Red; Metal Stocks Witness Buying(01:30 pm)

After opening the day on a negative note, share markets in India have continued the downtrend and are trading below the dotted line.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

The Real Reason Indiabulls Real Estate Jumped 42%(Daily Profit Hunter)

Apr 19, 2017

An elephant and six blind men will tell you more about the markets than any financial newspaper or channel.

In an Ocean of Corporate Defaulters, Vijay Mallya is a Small Fish(Vivek Kaul's Diary)

Apr 20, 2017

While it is important to get Mallya back to India, the government needs to show the same vigour in chasing defaulters of public sector bank loans residing in India.

4 Ways GST Will Impact The Mutual Fund Industry(Outside View)

Apr 19, 2017

PersonalFN explains how GST would impact India's mutual fund industry and investors

More

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - ALEMBIC PHARMA COMPARISON

Compare Company With Charts

COMPARE TORRENT PHARMA WITH

MARKET STATS